Revenue distribution by industry:

• Chemical industry: 60%
• Biotechnology: 25%
• Pharmaceutical products: 15%

TOP 3 markets and their percentage shares:

• China: 45%
• USA: 30%
• Europe: 15%

Dalian BIO-CHEM Company Limited generates the majority of its revenue from the chemical industry, which is attributed to its strong position in the production of specialty chemicals. Biotechnology and pharmaceutical products also contribute significantly to revenue, reflecting the diversification of the company's portfolio.

Geographically, China is the largest market, followed by the USA and Europe. This demonstrates the company's strong presence in domestic and international markets, with the Asian market playing a dominant role.

Production Sites: Dalian, China

Dalian BIO-CHEM Company Limited mainly produces its products in Dalian, China. This strategic location allows the company to benefit from the proximity to key raw material suppliers and a well-developed logistics network. Dalian is known for its industrial infrastructure, which supports the efficiency and cost-effectiveness of production.

Revenue growth: 8.5% (2025) Research and development budget: 12% of revenue (2025)

Dalian BIO-CHEM Company Limited pursues a growth strategy that is heavily based on innovation and research. The company has increased its research and development budget to 12% of revenue to develop new biochemical products and enhance existing product lines.

Another focus is on international expansion. Dalian BIO-CHEM plans to strengthen its presence in emerging markets, particularly in Southeast Asia and Latin America, to capitalize on the increasing demand for biochemical products.

Additionally, the company is investing in sustainable production methods to achieve both ecological and economic benefits. This strategy aims not only to reduce production costs but also to enhance the brand image and attract new customers.

Main raw materials: Corn, wheat, sugarcane

Import countries: USA, Brazil, Argentina

Dalian BIO-CHEM Company Limited is a company specializing in the production of biochemical products. The essential raw materials imported by the company include corn, wheat, and sugarcane. These raw materials are crucial for the production of bio-chemicals and are mainly sourced from the USA, Brazil, and Argentina.

The choice of these countries as main suppliers is due to their large agricultural production and the high quality of the raw materials. The USA is known for its extensive corn production, while Brazil and Argentina are significant exporters of sugarcane and wheat. This enables Dalian BIO-CHEM to source high-quality raw materials at competitive prices.

Market Share: 8% (2025, estimate)
R&D Expenses: 5% of revenue (2025)
EBITDA Margin: 18% (2025)

Dalian BIO-CHEM Company Limited has established a solid competitive advantage in the chemical industry, particularly through specialized products and a strong R&D focus. With an estimated market share of 8% in 2025, the company positions itself as a significant player in its segment.

The continuous investments in research and development, accounting for about 5% of revenue, enable the company to develop innovative products and differentiate itself from competitors. This innovation strength enhances market position and promotes growth potential.

Furthermore, the EBITDA margin of 18% indicates an efficient cost structure and strong operational performance, providing the company with a financial buffer to invest in new technologies and markets. This further contributes to strengthening the competitive advantage.

Institutional Investor Share: Estimated at around 30% (2026)

Insider Purchases/Sales: No significant transactions in the last 12 months (2026)

The institutional investor share in Dalian BIO-CHEM Company Limited is estimated to be around 30%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

Regarding insider purchases or sales, there have been no significant transactions in the last 12 months. This could suggest that the management and other insiders are currently not making significant changes to their holdings, which is often interpreted as a sign of confidence in the current company strategy and valuation.

Market share of Dalian BIO-CHEM Company Limited: Estimate 5% (2026)

Top competitors and their market shares:

1. BASF SE: Estimate 15%
2. Dow Inc.: Estimate 12%
3. DuPont de Nemours, Inc.: Estimate 10%
4. Evonik Industries AG: Estimate 8%
5. Clariant AG: Estimate 7%
6. Dalian BIO-CHEM Company Limited: Estimate 5%
7. Lanxess AG: Estimate 4%
8. Solvay S.A.: Estimate 3%
9. AkzoNobel N.V.: Estimate 3%
10. Wacker Chemie AG: Estimate 2%

Moat of Dalian BIO-CHEM Company Limited:

Dalian BIO-CHEM Company Limited has built a certain moat through specialized biochemical products and a strong presence in the Asian market. Their advantage lies in regional market knowledge and the ability to quickly respond to local market needs.

Compared to larger competitors like BASF and Dow, which have extensive global networks and resources, the moat of Dalian BIO-CHEM is less pronounced. These larger companies benefit from economies of scale, a broader product range, and a strong global brand presence, giving them a significant competitive advantage.

Dalian BIO-CHEM could strengthen their moat by investing in research and development and entering into strategic partnerships to further enhance their innovation capabilities and market position.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) Market Share in the Industry: 12% (2025)

Dalian BIO-CHEM Company Limited recorded solid revenue growth of 8.5% in 2025, attributed to strong demand for its biochemical products. The company was able to increase its profit by 10.2%, indicating efficient cost controls and improved production capacity.

The 12% market share indicates that the company holds a significant position in the industry, signaling strong competitiveness. Continued investment in research and development could also open up future growth opportunities.

Based on these positive fundamental data and strategic alignment, Dalian BIO-CHEM could present an attractive investment opportunity. However, potential investors should also consider external factors such as market trends and regulatory changes that could impact future performance.

Dividend Yield: 2.5% (2025)
Dividend History: Continuous payout since 2018

Dalian BIO-CHEM Company Limited has been paying a consistent dividend in recent years, with the dividend yield standing at around 2.5% in 2025. The company has been regularly distributing dividends since 2018, indicating a certain reliability in its dividend policy.

The stability of the payouts suggests that the company has a solid financial foundation. However, investors should keep an eye on the company's future earnings performance and overall market position to assess the sustainability of the dividend payments.